Study design and patient population
CM, nonmigraine, headache, migraine, migraine headache, disability
MIGRAINE, MIGRAINE HEADACHE
CONQUER (NCT03559257, N = 462) was a Phase 3, multicenter, randomized, double-blind, placebo-controlled study. The details on the study design and patient population have been previously published [Subgroup analyses were conducted based on EM and CM status as defined in the clinical trial protocol based on the baseline monthly migraine-headache days. CM was defined as ≥ 8 migraine headache days, with ≥ 15 headache days (migraine or nonmigraine). EM was defined as not meeting the criteria for CM and having at least 4 migraine headache days.Secondary objectives of the CONQUER study, among others, were to compare galcanezumab with placebo on changes in disability and quality of life using PRO measures. The objectives of this post-hoc analyses were to assess the reliability, validity, responsiveness and determine meaningful within-patient change thresholds for the WPAI domain scores.